Showing results (141-150 of 200) with videos related to

Sort By:
Pageof 20
Cancers|December 11, 2022
Impact of the Area of Residence of Ovarian Cancer Patients on Overall SurvivalFloriane Jochum, Anne-Sophie Hamy, Thomas Gaillard, et al.
Cancers|April 3, 2021
Patterns of Sequelae in Women with a History of Localized Breast Cancer: Results from the French VICAN SurveyLidia Delrieu, Liacine Bouaoun, Douae El Fatouhi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant ChemotherapyAnne-Sophie Hamy, Hélène Bonsang-Kitzis, Diane De Croze, et al.
European Radiology|June 15, 2023
Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapyCaroline Malhaire, Fatine Selhane, Marie-Judith Saint-Martin, et al.
Cancers|June 2, 2021
Breast Cancer (BC) Is a Window of Opportunity for Smoking Cessation: Results of a Retrospective Analysis of 1234 BC Survivors in Follow-Up ConsultationMarion Nicolas, Beatriz Grandal, Emma Dubost, et al.
JAMA Network Open|April 17, 2024
Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and NewbornsPaul Gougis, Anne-Sophie Hamy, Floriane Jochum, et al.
Breast Cancer Research : BCR|November 19, 2008
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancerFabien Reyal, Martin H van Vliet, Nicola J Armstrong, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2017
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 statusSylvie Giacchetti, Anne-Sophie Hamy, Suzette Delaloge, et al.
Cancers|October 16, 2024
Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of SurgeryGilles Houvenaeghel, Jean-Marc Classe, Marie-Pierre Chauvet, et al.
Journal of Inherited Metabolic Disease|May 20, 2021
OTC deficiency in females: Phenotype-genotype correlation based on a 130-family cohortStephanie Gobin-Limballe, Chris Ottolenghi, Fabien Reyal, et al.
Pageof 20